{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:10:34Z","timestamp":1793394634324,"version":"4.5.0"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12072-024-10692-4","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T11:00:35Z","timestamp":1721127635000},"page":"922-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-1494","authenticated-orcid":false,"given":"Maria Eva","family":"Argenziano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Na","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Montori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Bucchianico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Balducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Svegliati Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"issue":"2","key":"10692_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3350\/CMH.2022.0316","volume":"29","author":"S Choi","year":"2023","unstructured":"Choi S, Kim BK, Yon DK, et al. Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990\u20132019: A DALY-based analysis of the Global Burden of Disease 2019 study. Clin Mol Hepatol. 2023;29(2):433. https:\/\/doi.org\/10.3350\/CMH.2022.0316","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10692_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3350\/CMH.2021.0178","volume":"27","author":"SH Kang","year":"2021","unstructured":"Kang SH, Lee HW, Yoo JJ, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27(3):363. https:\/\/doi.org\/10.3350\/CMH.2021.0178","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"10692_CR3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3349\/YMJ.2022.0332","volume":"63","author":"HW Lee","year":"2022","unstructured":"Lee HW, Kim M, Youn J, Singh S, Ahn SH. Liver diseases in south korea: a pulse check of the public\u2019s knowledge, awareness, and behaviors. Yonsei Med J. 2022;63(12):1088\u20131098. https:\/\/doi.org\/10.3349\/YMJ.2022.0332","journal-title":"Yonsei Med J"},{"issue":"1","key":"10692_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/J.JHEP.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209. https:\/\/doi.org\/10.1016\/J.JHEP.2020.03.039","journal-title":"J Hepatol"},{"issue":"9","key":"10692_CR5","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/LIV.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082\u20132089. https:\/\/doi.org\/10.1111\/LIV.14548","journal-title":"Liver Int"},{"issue":"2","key":"10692_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/LIV.15139","volume":"42","author":"I Ayada","year":"2022","unstructured":"Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. Liver Int. 2022;42(2):277\u2013287. https:\/\/doi.org\/10.1111\/LIV.15139","journal-title":"Liver Int"},{"issue":"1","key":"10692_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3350\/CMH.2020.0176","volume":"27","author":"W Sohn","year":"2021","unstructured":"Sohn W, Lee HW, Lee S, et al. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol. 2021;27(1):157\u2013174. https:\/\/doi.org\/10.3350\/CMH.2020.0176","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10692_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/S41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223\u2013238. https:\/\/doi.org\/10.1038\/S41575-020-00381-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10692_CR9","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/HEP.31845","volume":"74","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Sharma R, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study. Hepatology. 2021;74(5):2410\u20132423. https:\/\/doi.org\/10.1002\/HEP.31845","journal-title":"Hepatology"},{"issue":"4","key":"10692_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/J.JHEP.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904. https:\/\/doi.org\/10.1016\/J.JHEP.2018.05.036","journal-title":"J Hepatol"},{"issue":"9","key":"10692_CR11","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/CLINEM\/DGAC321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691\u20132700. https:\/\/doi.org\/10.1210\/CLINEM\/DGAC321","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10692_CR12","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/J.CGH.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573\u2013e582. https:\/\/doi.org\/10.1016\/J.CGH.2021.02.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10692_CR13","unstructured":"World Obesity Atlas 2023 | World Obesity Federation. Accessed December 17, 2023. https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2023"},{"key":"10692_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324915","author":"A Vitale","year":"2023","unstructured":"Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: the ITALICA database. Gut. 2023. https:\/\/doi.org\/10.1136\/gutjnl-2021-324915","journal-title":"Gut"},{"key":"10692_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2021.100231","author":"S Myers","year":"2021","unstructured":"Myers S, Neyroud-Caspar I, Spahr L, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021. https:\/\/doi.org\/10.1016\/J.JHEPR.2021.100231","journal-title":"JHEP Rep."},{"key":"10692_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001921","author":"A Yeoh","year":"2023","unstructured":"Yeoh A, Yang Z, Cheung R, Do A, Ahmed A, Wong RJ. Incidence of cirrhosis and hepatocellular carcinoma among veterans with noncirrhotic metabolic dysfunction-associated fatty liver disease. J Clin Gastroenterol. 2023. https:\/\/doi.org\/10.1097\/MCG.0000000000001921","journal-title":"J Clin Gastroenterol"},{"key":"10692_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2023.100810","author":"BG Song","year":"2023","unstructured":"Song BG, Choi SC, Goh MJ, et al. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma. JHEP Rep. 2023. https:\/\/doi.org\/10.1016\/J.JHEPR.2023.100810","journal-title":"JHEP Rep."},{"issue":"7","key":"10692_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/APT.14937","volume":"48","author":"JG Stine","year":"2018","unstructured":"Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696\u2013703. https:\/\/doi.org\/10.1111\/APT.14937","journal-title":"Aliment Pharmacol Ther"},{"key":"10692_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/CTR.14965","author":"BTK Vanlerberghe","year":"2023","unstructured":"Vanlerberghe BTK, van Malenstein H, Sainz-Bariga M, et al. Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol-related liver disease. Clin Transplant. 2023. https:\/\/doi.org\/10.1111\/CTR.14965","journal-title":"Clin Transplant"},{"issue":"8","key":"10692_CR20","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/ANNONC\/MDU020","volume":"25","author":"F Turati","year":"2014","unstructured":"Turati F, Galeone C, Rota M, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol. 2014;25(8):1526\u20131535. https:\/\/doi.org\/10.1093\/ANNONC\/MDU020","journal-title":"Ann Oncol"},{"key":"10692_CR21","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2147\/CMAR.S368366","volume":"14","author":"J Xue","year":"2022","unstructured":"Xue J, Wang QX, Xiao HM, et al. Impact of metabolic dysfunction associated fatty liver disease on the prognosis of patients with hepatitis b virus-related hepatocellular carcinoma based on propensity score matching analysis. Cancer Manag Res. 2022;14:2193\u20132202. https:\/\/doi.org\/10.2147\/CMAR.S368366","journal-title":"Cancer Manag Res"},{"issue":"23","key":"10692_CR22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.21037\/ATM-21-3052","volume":"9","author":"D Jiang","year":"2021","unstructured":"Jiang D, Chen C, Liu X, et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. Ann Transl Med. 2021;9(23):1718\u20131718. https:\/\/doi.org\/10.21037\/ATM-21-3052","journal-title":"Ann Transl Med"},{"key":"10692_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2021.100350","author":"LA van Kleef","year":"2021","unstructured":"van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021. https:\/\/doi.org\/10.1016\/J.JHEPR.2021.100350","journal-title":"JHEP Rep."},{"key":"10692_CR24","doi-asserted-by":"publisher","unstructured":"Reggidori N, Bucci L, Santi V, Stefanini B, Lani L, Rampoldi D, Ghittoni G, Farinati F, Masotto A, Stefanini B, Mega A, Biasini E, Foschi FG, Svegliati-Baroni G, Sangiovanni A, Campani C, Raimondo G, Vidili G, Gasbarrini A, Celsa C, Di Marco M, Giannini EG, Sacco R, Brunetto MR, Azzaroli F, Magalotti D, Morisco F, Rapaccini GL, Nardone G, Vitale A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs. JHEP Rep. 2023 May 5;5(8):100784. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100784. PMID: 37520672; PMCID: PMC10382941.","DOI":"10.1016\/j.jhepr.2023.100784"},{"issue":"1","key":"10692_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/HEP4.1606","volume":"5","author":"VL Chen","year":"2021","unstructured":"Chen VL, Yeh ML, Yang JD, et al. Effects of cirrhosis and diagnosis scenario in metabolic-associated fatty liver disease-related hepatocellular carcinoma. Hepatol Commun. 2021;5(1):122\u2013132. https:\/\/doi.org\/10.1002\/HEP4.1606","journal-title":"Hepatol Commun"},{"issue":"4","key":"10692_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/AJE\/KWS252","volume":"177","author":"R Loomba","year":"2013","unstructured":"Loomba R, Yang HI, Su J, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013;177(4):333\u2013342. https:\/\/doi.org\/10.1093\/AJE\/KWS252","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10692_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/jhep.2002.33713","volume":"36","author":"S Nair","year":"2002","unstructured":"Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36(1):150\u2013155. https:\/\/doi.org\/10.1053\/jhep.2002.33713","journal-title":"Hepatology"},{"issue":"8","key":"10692_CR28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/J.CGH.2006.05.013","volume":"4","author":"G N\u2019Kontchou","year":"2006","unstructured":"N\u2019Kontchou G, Paries J, Htar MTT, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol. 2006;4(8):1062\u20131068. https:\/\/doi.org\/10.1016\/J.CGH.2006.05.013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10692_CR29","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/HEP.23527","volume":"51","author":"MS Ascha","year":"2010","unstructured":"Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972\u20131978. https:\/\/doi.org\/10.1002\/HEP.23527","journal-title":"Hepatology"},{"issue":"1","key":"10692_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/HEPR.13572","volume":"51","author":"Y Ochiai","year":"2021","unstructured":"Ochiai Y, Kawamura Y, Kobayashi M, et al. Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease. Hepatol Res. 2021;51(1):62\u201368. https:\/\/doi.org\/10.1111\/HEPR.13572","journal-title":"Hepatol Res"},{"issue":"5","key":"10692_CR31","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/HEP.29660","volume":"67","author":"TG Simon","year":"2018","unstructured":"Simon TG, King LY, Chong DQ, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology. 2018;67(5):1797\u20131806. https:\/\/doi.org\/10.1002\/HEP.29660","journal-title":"Hepatology"},{"issue":"1","key":"10692_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/AJG.2011.384","volume":"107","author":"SW Lai","year":"2012","unstructured":"Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107(1):46\u201352. https:\/\/doi.org\/10.1038\/AJG.2011.384","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10692_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/GUT.2004.052167","volume":"54","author":"JA Davila","year":"2005","unstructured":"Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54(4):533\u2013539. https:\/\/doi.org\/10.1136\/GUT.2004.052167","journal-title":"Gut"},{"issue":"8","key":"10692_CR34","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/IJC.34637","volume":"153","author":"MN Kim","year":"2023","unstructured":"Kim MN, Han K, Yoo J, Hwang SG, Zhang X, Ahn SH. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. Int J Cancer. 2023;153(8):1448\u20131458. https:\/\/doi.org\/10.1002\/IJC.34637","journal-title":"Int J Cancer"},{"issue":"3","key":"10692_CR35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/HEP.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020;71(3):808\u2013819. https:\/\/doi.org\/10.1002\/HEP.31014","journal-title":"Hepatology"},{"issue":"1","key":"10692_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/HEP.30623","volume":"70","author":"J Yang","year":"2019","unstructured":"Yang J, Tr\u00e9po E, Nahon P, et al. A 17-beta-hydroxysteroid dehydrogenase 13 variant protects from hepatocellular carcinoma development in alcoholic liver disease. Hepatology. 2019;70(1):231\u2013240. https:\/\/doi.org\/10.1002\/HEP.30623","journal-title":"Hepatology"},{"key":"10692_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-019-1321-X","author":"M Alexander","year":"2019","unstructured":"Alexander M, Loomis AK, Van Der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019. https:\/\/doi.org\/10.1186\/S12916-019-1321-X","journal-title":"BMC Med"},{"issue":"6","key":"10692_CR38","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1053\/J.GASTRO.2018.08.024","volume":"155","author":"F Kanwal","year":"2018","unstructured":"Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828-1837.e2. https:\/\/doi.org\/10.1053\/J.GASTRO.2018.08.024","journal-title":"Gastroenterology"},{"issue":"5","key":"10692_CR39","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/HEP.32792","volume":"77","author":"X Mao","year":"2023","unstructured":"Mao X, Cheung KS, Peng C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis. Hepatology. 2023;77(5):1735\u20131745. https:\/\/doi.org\/10.1002\/HEP.32792","journal-title":"Hepatology"},{"issue":"7","key":"10692_CR40","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/LIV.15577","volume":"43","author":"S Pelusi","year":"2023","unstructured":"Pelusi S, Bianco C, Colombo M, et al. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals. Liver Int. 2023;43(7):1593\u20131603. https:\/\/doi.org\/10.1111\/LIV.15577","journal-title":"Liver Int"},{"issue":"6","key":"10692_CR41","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/J.CGH.2018.10.017","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee Y, Doumouras AG, Yu J, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040-1060.e11. https:\/\/doi.org\/10.1016\/J.CGH.2018.10.017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10692_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/JGH.14448","volume":"34","author":"T Ito","year":"2019","unstructured":"Ito T, Ishigami M, Ishizu Y, et al. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol. 2019;34(1):207\u2013214. https:\/\/doi.org\/10.1111\/JGH.14448","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10692_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/JEBM.12270","volume":"10","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O, Helbling D, Sch\u00f6b O, et al. Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: an updated systematic review of 81 epidemiological studies. J Evid Based Med. 2017;10(4):245\u2013254. https:\/\/doi.org\/10.1111\/JEBM.12270","journal-title":"J Evid Based Med"},{"key":"10692_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/JCM12093336","author":"JJ Yoo","year":"2023","unstructured":"Yoo JJ, Park MY, Cho EJ, et al. Smoking increases the risk of hepatocellular carcinoma and cardiovascular disease in patients with metabolic-associated fatty liver disease. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/JCM12093336","journal-title":"J Clin Med"},{"key":"10692_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.33305","author":"S Hwang","year":"2021","unstructured":"Hwang S, Park YM, Do HK, et al. Associations of general obesity and central obesity with the risk of hepatocellular carcinoma in a Korean population: a national population-based cohort study. Int J Cancer. 2021. https:\/\/doi.org\/10.1002\/IJC.33305","journal-title":"Int J Cancer"},{"issue":"5","key":"10692_CR46","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1016\/J.CGH.2021.06.042","volume":"20","author":"W Sohn","year":"2022","unstructured":"Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK. Liver fibrosis in asians with metabolic dysfunction-associated fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(5):e1135\u2013e1148. https:\/\/doi.org\/10.1016\/J.CGH.2021.06.042","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"14","key":"10692_CR47","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/J.EJCA.2012.02.063","volume":"48","author":"Y Chen","year":"2012","unstructured":"Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012;48(14):2137\u20132145. https:\/\/doi.org\/10.1016\/J.EJCA.2012.02.063","journal-title":"Eur J Cancer"},{"issue":"5","key":"10692_CR48","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"issue":"12","key":"10692_CR49","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/HEPR.13830","volume":"52","author":"B Yun","year":"2022","unstructured":"Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: a nationwide study. Hepatol Res. 2022;52(12):975\u2013984. https:\/\/doi.org\/10.1111\/HEPR.13830","journal-title":"Hepatol Res"},{"issue":"5","key":"10692_CR50","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/S12072-023-10545-6","volume":"17","author":"SC Huang","year":"2023","unstructured":"Huang SC, Su TH, Tseng TC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17(5):1139\u20131149. https:\/\/doi.org\/10.1007\/S12072-023-10545-6","journal-title":"Hepatol Int"},{"issue":"2","key":"10692_CR51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/INFDIS\/JIAA739","volume":"224","author":"J Li","year":"2021","unstructured":"Li J, Yang HI, Yeh ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis. 2021;224(2):294\u2013302. https:\/\/doi.org\/10.1093\/INFDIS\/JIAA739","journal-title":"J Infect Dis"},{"key":"10692_CR52","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.2147\/DMSO.S416280","volume":"16","author":"Y You","year":"2023","unstructured":"You Y, Yang T, Wei S, et al. Survival of patients with hepatitis b-related hepatocellular carcinoma with concomitant metabolic associated fatty liver disease. Diabetes Metab Syndr Obes. 2023;16:2283\u20132293. https:\/\/doi.org\/10.2147\/DMSO.S416280","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"10692_CR53","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/S12072-021-10218-2","volume":"15","author":"LY Mak","year":"2021","unstructured":"Mak LY, Hui RWH, Fung J, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int. 2021;15(4):901\u2013911. https:\/\/doi.org\/10.1007\/S12072-021-10218-2","journal-title":"Hepatol Int"},{"issue":"7","key":"10692_CR54","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1007\/S10620-020-06457-2","volume":"66","author":"JN Benhammou","year":"2021","unstructured":"Benhammou JN, Moon AM, Pisegna JR, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. Dig Dis Sci. 2021;66(7):2394\u20132406. https:\/\/doi.org\/10.1007\/S10620-020-06457-2","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10692_CR55","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/J.JHEP.2016.10.017","volume":"66","author":"AJ van der Meer","year":"2017","unstructured":"van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66(3):485\u2013493. https:\/\/doi.org\/10.1016\/J.JHEP.2016.10.017","journal-title":"J Hepatol"},{"key":"10692_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/J.METOP.2021.100090","author":"D Ji","year":"2021","unstructured":"Ji D, Chen GF, Niu XX, et al. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: a prospective four-years follow-up study. Metabol Open. 2021. https:\/\/doi.org\/10.1016\/J.METOP.2021.100090","journal-title":"Metabol Open"},{"issue":"6","key":"10692_CR57","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/J.GASTRO.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611-1625.e12. https:\/\/doi.org\/10.1053\/J.GASTRO.2020.01.043","journal-title":"Gastroenterology"},{"key":"10692_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/J.CGH.2012.10.001","author":"DL White","year":"2012","unstructured":"White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012. https:\/\/doi.org\/10.1016\/J.CGH.2012.10.001","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10692_CR59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/gast.2002.34168","volume":"123","author":"E Bugianesi","year":"2002","unstructured":"Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134\u2013140. https:\/\/doi.org\/10.1053\/gast.2002.34168","journal-title":"Gastroenterology"},{"issue":"17","key":"10692_CR60","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMOA2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559\u20131569. https:\/\/doi.org\/10.1056\/NEJMOA2029349","journal-title":"N Engl J Med"},{"issue":"2","key":"10692_CR61","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/J.GASTRO.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort Study. Gastroenterology. 2018;155(2):443-457.e17. https:\/\/doi.org\/10.1053\/J.GASTRO.2018.04.034","journal-title":"Gastroenterology"},{"issue":"4","key":"10692_CR62","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","volume":"23","author":"DJH Tan","year":"2022","unstructured":"Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521. https:\/\/doi.org\/10.1016\/S1470-2045(22)00078-X","journal-title":"Lancet Oncol"},{"issue":"12","key":"10692_CR63","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1007\/S00535-009-0112-0","volume":"44","author":"N Kawada","year":"2009","unstructured":"Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(12):1190\u20131194. https:\/\/doi.org\/10.1007\/S00535-009-0112-0","journal-title":"J Gastroenterol"},{"issue":"5","key":"10692_CR64","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/J.CGH.2011.01.023","volume":"9","author":"K Yasui","year":"2011","unstructured":"Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9(5):428\u2013433. https:\/\/doi.org\/10.1016\/J.CGH.2011.01.023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10692_CR65","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1007\/S10620-015-3821-7","volume":"60","author":"RB Perumpail","year":"2015","unstructured":"Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci. 2015;60(10):3142\u20133148. https:\/\/doi.org\/10.1007\/S10620-015-3821-7","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10692_CR66","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/HEP.22734","volume":"49","author":"V Paradis","year":"2009","unstructured":"Paradis V, Zalisnski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49(3):851\u2013859. https:\/\/doi.org\/10.1002\/HEP.22734","journal-title":"Hepatology"},{"issue":"6","key":"10692_CR67","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/HEP.28123","volume":"62","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723\u20131730. https:\/\/doi.org\/10.1002\/HEP.28123","journal-title":"Hepatology"},{"issue":"3","key":"10692_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/J.CGH.2005.12.007","volume":"4","author":"HB El-Serag","year":"2006","unstructured":"El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369\u2013380. https:\/\/doi.org\/10.1016\/J.CGH.2005.12.007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10692_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/DMRR.1291","volume":"28","author":"P Wang","year":"2012","unstructured":"Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28(2):109\u2013122. https:\/\/doi.org\/10.1002\/DMRR.1291","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"10692_CR70","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/IJC.26165","volume":"130","author":"C Wang","year":"2012","unstructured":"Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639\u20131648. https:\/\/doi.org\/10.1002\/IJC.26165","journal-title":"Int J Cancer"},{"issue":"3","key":"10692_CR71","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/HEP.30858","volume":"71","author":"JD Yang","year":"2020","unstructured":"Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology. 2020;71(3):907\u2013916. https:\/\/doi.org\/10.1002\/HEP.30858","journal-title":"Hepatology"},{"issue":"4","key":"10692_CR72","doi-asserted-by":"publisher","first-page":"610","DOI":"10.5009\/GNL220400","volume":"17","author":"TS Lim","year":"2023","unstructured":"Lim TS, Chun HS, Kim SS, et al. Fibrotic burden in the liver differs across metabolic dysfunction-associated fatty liver disease subtypes. Gut Liver. 2023;17(4):610\u2013619. https:\/\/doi.org\/10.5009\/GNL220400","journal-title":"Gut Liver"},{"issue":"7","key":"10692_CR73","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/S41416-018-0007-Z","volume":"118","author":"JL Petrick","year":"2018","unstructured":"Petrick JL, Campbell PT, Koshiol J, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Br J Cancer. 2018;118(7):1005\u20131012. https:\/\/doi.org\/10.1038\/S41416-018-0007-Z","journal-title":"Br J Cancer"},{"issue":"1","key":"10692_CR74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.JHEP.2014.02.030","volume":"61","author":"YL Liu","year":"2014","unstructured":"Liu YL, Patman GL, Leathart JBS, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014;61(1):75\u201381. https:\/\/doi.org\/10.1016\/J.JHEP.2014.02.030","journal-title":"J Hepatol"},{"issue":"3","key":"10692_CR75","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/AJG.2013.476","volume":"109","author":"AG Singal","year":"2014","unstructured":"Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109(3):325\u2013334. https:\/\/doi.org\/10.1038\/AJG.2013.476","journal-title":"Am J Gastroenterol"},{"key":"10692_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/NCOMMS5309","author":"YL Liu","year":"2014","unstructured":"Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014. https:\/\/doi.org\/10.1038\/NCOMMS5309","journal-title":"Nat Commun"},{"key":"10692_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0185490","author":"T Kawaguchi","year":"2018","unstructured":"Kawaguchi T, Shima T, Mizuno M, et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0185490","journal-title":"PLoS ONE"},{"key":"10692_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-04991-0","author":"B Donati","year":"2017","unstructured":"Donati B, Dongiovanni P, Romeo S, et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/S41598-017-04991-0","journal-title":"Sci Rep"},{"issue":"1","key":"10692_CR79","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/HEP.30799","volume":"71","author":"H Gellert-Kristensen","year":"2020","unstructured":"Gellert-Kristensen H, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Stender S. High risk of fatty liver disease amplifies the alanine transaminase-lowering effect of a HSD17B13 variant. Hepatology. 2020;71(1):56\u201366. https:\/\/doi.org\/10.1002\/HEP.30799","journal-title":"Hepatology"},{"issue":"3","key":"10692_CR80","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/HEP.31238","volume":"72","author":"H Gellert-Kristensen","year":"2020","unstructured":"Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology. 2020;72(3):845\u2013856. https:\/\/doi.org\/10.1002\/HEP.31238","journal-title":"Hepatology"},{"issue":"4","key":"10692_CR81","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/J.JHEP.2020.11.024","volume":"74","author":"C Bianco","year":"2021","unstructured":"Bianco C, Jamialahmadi O, Pelusi S, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74(4):775. https:\/\/doi.org\/10.1016\/J.JHEP.2020.11.024","journal-title":"J Hepatol"},{"key":"10692_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-020-20422-7","author":"J Behary","year":"2021","unstructured":"Behary J, Amorim N, Jiang XT, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/S41467-020-20422-7","journal-title":"Nat Commun"},{"issue":"1","key":"10692_CR83","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/HEP.30036","volume":"69","author":"FR Ponziani","year":"2019","unstructured":"Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69(1):107\u2013120. https:\/\/doi.org\/10.1002\/HEP.30036","journal-title":"Hepatology"},{"issue":"14","key":"10692_CR84","doi-asserted-by":"publisher","first-page":"18229","DOI":"10.18632\/ONCOTARGET.7571","volume":"7","author":"CY Ku","year":"2016","unstructured":"Ku CY, Liu YH, Lin HY, Lu SC, Lin JY. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma. Oncotarget. 2016;7(14):18229\u201318246. https:\/\/doi.org\/10.18632\/ONCOTARGET.7571","journal-title":"Oncotarget"},{"issue":"5930","key":"10692_CR85","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/SCIENCE.1160809","volume":"324","author":"MGV Heiden","year":"2009","unstructured":"Heiden MGV, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029. https:\/\/doi.org\/10.1126\/SCIENCE.1160809","journal-title":"Science"},{"issue":"2","key":"10692_CR86","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022;12(2):558\u2013580. https:\/\/doi.org\/10.1016\/j.apsb.2021.09.019","journal-title":"Acta Pharm Sin B"},{"key":"10692_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/S13046-019-1131-1","author":"Z Qin","year":"2019","unstructured":"Qin Z, Xiang C, Zhong F, et al. Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner. J Exp Clin Cancer Res. 2019. https:\/\/doi.org\/10.1186\/S13046-019-1131-1","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10692_CR88","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1136\/GUTJNL-2013-305302","volume":"63","author":"X Hong","year":"2014","unstructured":"Hong X, Song R, Song H, et al. PTEN antagonises Tcl1\/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut. 2014;63(10):1635\u20131647. https:\/\/doi.org\/10.1136\/GUTJNL-2013-305302","journal-title":"Gut"},{"issue":"6","key":"10692_CR89","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/S41556-020-0511-2","volume":"22","author":"F Li","year":"2020","unstructured":"Li F, Huangyang P, Burrows M, et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. Nat Cell Biol. 2020;22(6):728\u2013739. https:\/\/doi.org\/10.1038\/S41556-020-0511-2","journal-title":"Nat Cell Biol"},{"issue":"7804","key":"10692_CR90","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/S41586-020-2183-2","volume":"580","author":"D Xu","year":"2020","unstructured":"Xu D, Wang Z, Xia Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1\/2 for lipogenesis. Nature. 2020;580(7804):530\u2013535. https:\/\/doi.org\/10.1038\/S41586-020-2183-2","journal-title":"Nature"},{"key":"10692_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/S42003-020-01367-5","author":"J Seo","year":"2020","unstructured":"Seo J, Jeong DW, Park JW, Lee KW, Fukuda J, Chun YS. Fatty-acid-induced FABP5\/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun Biol. 2020. https:\/\/doi.org\/10.1038\/S42003-020-01367-5","journal-title":"Commun Biol."},{"issue":"1","key":"10692_CR92","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/J.CCELL.2016.05.020","volume":"30","author":"AL Gomes","year":"2016","unstructured":"Gomes AL, Teijeiro A, Bur\u00e9n S, et al. Metabolic inflammation-associated il-17a causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30(1):161\u2013175. https:\/\/doi.org\/10.1016\/J.CCELL.2016.05.020","journal-title":"Cancer Cell"},{"issue":"12","key":"10692_CR93","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/NM.3372","volume":"19","author":"MD Fullerton","year":"2013","unstructured":"Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013;19(12):1649\u20131654. https:\/\/doi.org\/10.1038\/NM.3372","journal-title":"Nat Med"},{"key":"10692_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-022-29846-9","author":"Z Ning","year":"2022","unstructured":"Ning Z, Guo X, Liu X, et al. USP22 regulates lipidome accumulation by stabilizing PPAR\u03b3 in hepatocellular carcinoma. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/S41467-022-29846-9","journal-title":"Nat Commun"},{"issue":"3","key":"10692_CR95","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00041433-200306000-00005","volume":"14","author":"JM Ntambi","year":"2003","unstructured":"Ntambi JM, Miyazaki M. Recent insights into stearoyl-CoA desaturase-1. Curr Opin Lipidol. 2003;14(3):255\u2013261. https:\/\/doi.org\/10.1097\/00041433-200306000-00005","journal-title":"Curr Opin Lipidol"},{"key":"10692_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/S41389-020-0226-Z","author":"J Chen","year":"2020","unstructured":"Chen J, Ding C, Chen Y, et al. ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK\/FBW7\/c-Myc axis. Oncogenesis. 2020. https:\/\/doi.org\/10.1038\/S41389-020-0226-Z","journal-title":"Oncogenesis"},{"issue":"10","key":"10692_CR97","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.4161\/CC.20259","volume":"11","author":"EK Daugherity","year":"2012","unstructured":"Daugherity EK, Balmus G, Al Saei A, et al. The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle. 2012;11(10):1918\u20131928. https:\/\/doi.org\/10.4161\/CC.20259","journal-title":"Cell Cycle"},{"issue":"5","key":"10692_CR98","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/J.CELL.2018.09.053","volume":"175","author":"M Grohmann","year":"2018","unstructured":"Grohmann M, Wiede F, Dodd GT, et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent hcc. Cell. 2018;175(5):1289-1306.e20. https:\/\/doi.org\/10.1016\/J.CELL.2018.09.053","journal-title":"Cell"},{"issue":"5","key":"10692_CR99","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/HEP.23892","volume":"52","author":"D Sharma","year":"2010","unstructured":"Sharma D, Wang J, Fu PP, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010;52(5):1713\u20131722. https:\/\/doi.org\/10.1002\/HEP.23892","journal-title":"Hepatology"},{"issue":"5","key":"10692_CR100","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/J.JHEP.2021.12.012","volume":"76","author":"O Govaere","year":"2022","unstructured":"Govaere O, Petersen SK, Martinez-Lopez N, et al. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. J Hepatol. 2022;76(5):1001\u20131012. https:\/\/doi.org\/10.1016\/J.JHEP.2021.12.012","journal-title":"J Hepatol"},{"issue":"7854","key":"10692_CR101","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/S41586-021-03233-8","volume":"592","author":"M Dudek","year":"2021","unstructured":"Dudek M, Pfister D, Donakonda S, et al. Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH. Nature. 2021;592(7854):444\u2013449. https:\/\/doi.org\/10.1038\/S41586-021-03233-8","journal-title":"Nature"},{"issue":"4","key":"10692_CR102","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/HEP4.1479","volume":"4","author":"G Parthasarathy","year":"2020","unstructured":"Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun. 2020;4(4):478\u2013492. https:\/\/doi.org\/10.1002\/HEP4.1479","journal-title":"Hepatol Commun"},{"key":"10692_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA59081427","author":"L Abenavoli","year":"2023","unstructured":"Abenavoli L, Montori M, Svegliati Baroni G, et al. Perspective on the role of gut microbiome in the treatment of hepatocellular carcinoma with immune checkpoint inhibitors. Medicina (Kaunas). 2023. https:\/\/doi.org\/10.3390\/MEDICINA59081427","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10692_CR104","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1535370219898141","volume":"245","author":"D Dhar","year":"2020","unstructured":"Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood). 2020;245(2):96\u2013108. https:\/\/doi.org\/10.1177\/1535370219898141","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"10692_CR105","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/HEP.31771","volume":"74","author":"EP Newberry","year":"2021","unstructured":"Newberry EP, Hall Z, Xie Y, et al. Liver-specific deletion of mouse tm6sf2 promotes steatosis, fibrosis, and hepatocellular cancer. Hepatology. 2021;74(3):1203\u20131219. https:\/\/doi.org\/10.1002\/HEP.31771","journal-title":"Hepatology"},{"issue":"1","key":"10692_CR106","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/J.JHEP.2020.08.027","volume":"74","author":"K Teo","year":"2021","unstructured":"Teo K, Abeysekera KWM, Adams L, et al. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. J Hepatol. 2021;74(1):20\u201330. https:\/\/doi.org\/10.1016\/J.JHEP.2020.08.027","journal-title":"J Hepatol"},{"issue":"5","key":"10692_CR107","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/S12072-023-10568-Z","volume":"17","author":"K Vaz","year":"2023","unstructured":"Vaz K, Clayton-Chubb D, Majeed A, et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int. 2023;17(5):1082\u20131097. https:\/\/doi.org\/10.1007\/S12072-023-10568-Z","journal-title":"Hepatol Int"},{"key":"10692_CR108","unstructured":"Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int. 2005;4(2):173\u2013177. Accessed December 21, 2023. https:\/\/europepmc.org\/article\/med\/15908310"},{"issue":"2","key":"10692_CR109","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/J.JHEP.2019.08.025","volume":"72","author":"AG Singal","year":"2020","unstructured":"Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250\u2013261. https:\/\/doi.org\/10.1016\/J.JHEP.2019.08.025","journal-title":"J Hepatol"},{"issue":"3","key":"10692_CR110","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/AJG.2012.449","volume":"108","author":"AG Singal","year":"2013","unstructured":"Singal AG, Nehra M, Adams-Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108(3):425\u2013432. https:\/\/doi.org\/10.1038\/AJG.2012.449","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10692_CR111","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/S00330-014-3173-2","volume":"24","author":"M Di Martino","year":"2014","unstructured":"Di Martino M, Saba L, Bosco S, et al. Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings. Eur Radiol. 2014;24(7):1446\u20131454. https:\/\/doi.org\/10.1007\/S00330-014-3173-2","journal-title":"Eur Radiol"},{"issue":"3","key":"10692_CR112","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/J.DIII.2015.09.007","volume":"97","author":"M Lafitte","year":"2016","unstructured":"Lafitte M, Laurent V, Soyer P, et al. MDCT features of hepatocellular carcinoma (HCC) in non-cirrhotic liver. Diagn Interv Imaging. 2016;97(3):355\u2013360. https:\/\/doi.org\/10.1016\/J.DIII.2015.09.007","journal-title":"Diagn Interv Imaging"},{"key":"10692_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJRAD.2021.109651","author":"M Barat","year":"2021","unstructured":"Barat M, Nguyen TTL, Hollande C, et al. LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI? Eur J Radiol. 2021. https:\/\/doi.org\/10.1016\/J.EJRAD.2021.109651","journal-title":"Eur J Radiol"},{"key":"10692_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJRAD.2019.108648","author":"F Al-Sharhan","year":"2019","unstructured":"Al-Sharhan F, Dohan A, Barat M, et al. MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH). Eur J Radiol. 2019. https:\/\/doi.org\/10.1016\/J.EJRAD.2019.108648","journal-title":"Eur J Radiol"},{"issue":"5","key":"10692_CR115","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1007\/S00261-016-1002-6","volume":"42","author":"SK Venkatesh","year":"2017","unstructured":"Venkatesh SK, Hennedige T, Johnson GB, Hough DM, Fletcher JG. Imaging patterns and focal lesions in fatty liver: a pictorial review. Abdom Radiol (NY). 2017;42(5):1374\u20131392. https:\/\/doi.org\/10.1007\/S00261-016-1002-6","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"10692_CR116","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000525911","volume":"12","author":"H Lu","year":"2022","unstructured":"Lu H, George J, Eslam M, et al. Discriminatory changes in circulating metabolites as a predictor of hepatocellular cancer in patients with metabolic (dysfunction) associated fatty liver disease. Liver Cancer. 2022;12(1):19\u201331. https:\/\/doi.org\/10.1159\/000525911","journal-title":"Liver Cancer"},{"issue":"1","key":"10692_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/METABO11010054","volume":"11","author":"B Buchard","year":"2021","unstructured":"Buchard B, Teilhet C, Samarakoon NA, et al. Two metabolomics phenotypes of human hepatocellular carcinoma in non-alcoholic fatty liver disease according to fibrosis severity. Metabolites. 2021;11(1):1\u201319. https:\/\/doi.org\/10.3390\/METABO11010054","journal-title":"Metabolites"},{"issue":"9","key":"10692_CR118","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1245\/S10434-012-2300-Z","volume":"19","author":"CS Van Kessel","year":"2012","unstructured":"Van Kessel CS, Buckens CFM, Van Den Bosch MAAJ, Van Leeuwen MS, Van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19(9):2805\u20132813. https:\/\/doi.org\/10.1245\/S10434-012-2300-Z","journal-title":"Ann Surg Oncol"},{"key":"10692_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJRAD.2010.03.004","author":"V Kulemann","year":"2011","unstructured":"Kulemann V, Schima W, Tamandl D, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol. 2011. https:\/\/doi.org\/10.1016\/J.EJRAD.2010.03.004","journal-title":"Eur J Radiol"},{"issue":"22","key":"10692_CR120","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3748\/WJG.V24.I22.2348","volume":"24","author":"HY Jiang","year":"2018","unstructured":"Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol. 2018;24(22):2348. https:\/\/doi.org\/10.3748\/WJG.V24.I22.2348","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10692_CR121","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/J.ULTRASMEDBIO.2020.04.030","volume":"46","author":"CF Dietrich","year":"2020","unstructured":"Dietrich CF, Nols\u00f8e CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (ceus) in the liver-update 2020 wfumb in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol. 2020;46(10):2579\u20132604. https:\/\/doi.org\/10.1016\/J.ULTRASMEDBIO.2020.04.030","journal-title":"Ultrasound Med Biol"},{"issue":"4","key":"10692_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS13040790","volume":"13","author":"M Lupsor-Platon","year":"2021","unstructured":"Lupsor-Platon M, Serban T, Silion AI, Tirpe GR, Tirpe A, Florea M. Performance of ultrasound techniques and the potential of artificial intelligence in the evaluation of hepatocellular carcinoma and non-alcoholic fatty liver disease. Cancers (Basel). 2021;13(4):1\u201323. https:\/\/doi.org\/10.3390\/CANCERS13040790","journal-title":"Cancers (Basel)"},{"key":"10692_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/JCM11216368","author":"A Martinino","year":"2022","unstructured":"Martinino A, Aloulou M, Chatterjee S, et al. Artificial intelligence in the diagnosis of hepatocellular carcinoma: a systematic review. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/JCM11216368","journal-title":"J Clin Med"},{"issue":"1","key":"10692_CR124","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/J.JHEP.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/J.JHEP.2018.03.019","journal-title":"J Hepatol"},{"key":"10692_CR125","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2021.08","author":"MS Torbenson","year":"2021","unstructured":"Torbenson MS, Yeh MM. Steatohepatitic hepatocellular carcinoma. Hepatoma Res. 2021. https:\/\/doi.org\/10.20517\/2394-5079.2021.08","journal-title":"Hepatoma Res"},{"issue":"4","key":"10692_CR126","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/JAMAONCOL.2016.3147","volume":"3","author":"SY Kim","year":"2017","unstructured":"Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3(4):456\u2013463. https:\/\/doi.org\/10.1001\/JAMAONCOL.2016.3147","journal-title":"JAMA Oncol"},{"issue":"1","key":"10692_CR127","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/J.CGH.2021.08.010","volume":"20","author":"NP Chalasani","year":"2022","unstructured":"Chalasani NP, Porter K, Bhattacharya A, et al. Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2022;20(1):173-182.e7. https:\/\/doi.org\/10.1016\/J.CGH.2021.08.010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10692_CR128","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/TP.0000000000002043","volume":"102","author":"EM Sadler","year":"2018","unstructured":"Sadler EM, Mehta N, Bhat M, et al. Liver transplantation for nash-related hepatocellular carcinoma versus non-nash etiologies of hepatocellular carcinoma. Transplantation. 2018;102(4):640\u2013647. https:\/\/doi.org\/10.1097\/TP.0000000000002043","journal-title":"Transplantation"},{"issue":"3","key":"10692_CR129","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/J.JHEP.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u2013693. https:\/\/doi.org\/10.1016\/J.JHEP.2021.11.018","journal-title":"J Hepatol"},{"issue":"8","key":"10692_CR130","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/LIV.14154","volume":"39","author":"A Vitale","year":"2019","unstructured":"Vitale A, Farinati F, Pawlik TM, et al. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. Liver Int. 2019;39(8):1478\u20131489. https:\/\/doi.org\/10.1111\/LIV.14154","journal-title":"Liver Int"},{"key":"10692_CR131","doi-asserted-by":"publisher","DOI":"10.1093\/BJSOPEN\/ZRAC167","author":"JY Su","year":"2023","unstructured":"Su JY, Deng ZJ, Teng YX, et al. Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis. BJS Open. 2023. https:\/\/doi.org\/10.1093\/BJSOPEN\/ZRAC167","journal-title":"BJS Open."},{"issue":"3","key":"10692_CR132","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/J.CGH.2020.05.064","volume":"19","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):580-589.e5. https:\/\/doi.org\/10.1016\/J.CGH.2020.05.064","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10692_CR133","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/TP.0000000000002355","volume":"103","author":"PJ Thuluvath","year":"2019","unstructured":"Thuluvath PJ, Hanish S, Savva Y. Waiting list mortality and transplant rates for NASH cirrhosis when compared with cryptogenic, alcoholic, or AIH cirrhosis. Transplantation. 2019;103(1):113\u2013121. https:\/\/doi.org\/10.1097\/TP.0000000000002355","journal-title":"Transplantation"},{"issue":"1","key":"10692_CR134","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/J.DLD.2017.08.022","volume":"50","author":"EH van den Berg","year":"2018","unstructured":"van den Berg EH, Douwes RM, de Meijer VE, Schreuder TCMA, Blokzijl H. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Dig Liver Dis. 2018;50(1):68\u201375. https:\/\/doi.org\/10.1016\/J.DLD.2017.08.022","journal-title":"Dig Liver Dis"},{"issue":"13","key":"10692_CR135","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/J.CGH.2019.04.033","volume":"17","author":"S Nagai","year":"2019","unstructured":"Nagai S, Collins K, Chau LC, et al. Increased risk of death in first year after liver transplantation among patients with nonalcoholic steatohepatitis vs liver disease of other etiologies. Clin Gastroenterol Hepatol. 2019;17(13):2759-2768.e5. https:\/\/doi.org\/10.1016\/J.CGH.2019.04.033","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10692_CR136","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.JHEP.2019.04.011","volume":"71","author":"D Haldar","year":"2019","unstructured":"Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study. J Hepatol. 2019;71(2):313\u2013322. https:\/\/doi.org\/10.1016\/J.JHEP.2019.04.011","journal-title":"J Hepatol"},{"issue":"5","key":"10692_CR137","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/J.HPB.2023.01.019","volume":"25","author":"L Rajendran","year":"2023","unstructured":"Rajendran L, Murillo Perez CF, Ivanics T, et al. Outcomes of liver transplantation in non-alcoholic steatohepatitis (NASH) versus non-NASH associated hepatocellular carcinoma. HPB (Oxford). 2023;25(5):556\u2013567. https:\/\/doi.org\/10.1016\/J.HPB.2023.01.019","journal-title":"HPB (Oxford)"},{"key":"10692_CR138","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13760","author":"J Liang","year":"2019","unstructured":"Liang J, Ariizumi SI, Nakano M, Yamamoto M. Diabetes mellitus and\/or nonalcoholic steatohepatitis-related hepatocellular carcinoma showed favorable surgical outcomes after hepatectomy. Anticancer Res. 2019. https:\/\/doi.org\/10.21873\/anticanres.13760","journal-title":"Anticancer Res"},{"key":"10692_CR139","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14342","author":"CR Wong","year":"2017","unstructured":"Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017. https:\/\/doi.org\/10.1111\/apt.14342","journal-title":"Aliment Pharmacol Ther"},{"key":"10692_CR140","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15129","author":"N Nguyen","year":"2022","unstructured":"Nguyen N, Rode A, Trillaud H, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. Liver Int. 2022. https:\/\/doi.org\/10.1111\/liv.15129","journal-title":"Liver Int"},{"key":"10692_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0145-7","author":"QM Anstee","year":"2019","unstructured":"Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.1038\/s41575-019-0145-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10692_CR142","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-019-02363-x","author":"S Young","year":"2020","unstructured":"Young S, Sanghvi T, Rubin N, et al. Transarterial chemoembolization of hepatocellular carcinoma: propensity score matching study comparing survival and complications in patients with nonalcoholic steatohepatitis versus other causes cirrhosis. Cardiovasc Intervent Radiol. 2020. https:\/\/doi.org\/10.1007\/s00270-019-02363-x","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10692_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2016.06.002","author":"SE Wu","year":"2017","unstructured":"Wu SE, Charles HW, Park JS, Goldenberg AS, Deipolyi AR. Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Diagn Interv Imaging. 2017. https:\/\/doi.org\/10.1016\/j.diii.2016.06.002","journal-title":"Diagn Interv Imaging"},{"key":"10692_CR144","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018171768","author":"RJ Lewandowski","year":"2018","unstructured":"Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018. https:\/\/doi.org\/10.1148\/radiol.2018171768","journal-title":"Radiology"},{"key":"10692_CR145","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02695.x","author":"RJ Lewandowski","year":"2009","unstructured":"Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02695.x","journal-title":"Am J Transplant"},{"key":"10692_CR146","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29691","author":"R Salem","year":"2018","unstructured":"Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1000-patient 15-year experience. Hepatology. 2018. https:\/\/doi.org\/10.1002\/hep.29691","journal-title":"Hepatology"},{"key":"10692_CR147","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.199752","author":"N Abouchaleh","year":"2018","unstructured":"Abouchaleh N, Gabr A, Ali R, et al. 90 Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: Long-term outcomes in a 185-patient cohort. J Nucl Med. 2018. https:\/\/doi.org\/10.2967\/jnumed.117.199752","journal-title":"J Nucl Med"},{"key":"10692_CR148","doi-asserted-by":"publisher","DOI":"10.1159\/000501484","author":"C Schotten","year":"2019","unstructured":"Schotten C, Bechmann LP, Manka P, et al. NAFLD-associated comorbidities in advanced stage hcc do not alter the safety and efficacy of yttrium-90 radioembolization. Liver Cancer. 2019. https:\/\/doi.org\/10.1159\/000501484","journal-title":"Liver Cancer."},{"key":"10692_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00350-4","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res. 2022. https:\/\/doi.org\/10.1186\/s40364-021-00350-4","journal-title":"Biomark Res."},{"key":"10692_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.737497","author":"HT Liu","year":"2021","unstructured":"Liu HT, Jiang MJ, Deng ZJ, et al. Immune checkpoint inhibitors in hepatocellular carcinoma: current progresses and challenges. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.737497","journal-title":"Front Oncol"},{"key":"10692_CR151","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2021.00179","author":"ZJ Deng","year":"2022","unstructured":"Deng ZJ, Li L, Teng YX, et al. Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy. J Clin Transl Hepatol. 2022. https:\/\/doi.org\/10.14218\/JCTH.2021.00179","journal-title":"J Clin Transl Hepatol"},{"key":"10692_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet. 2018. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1","journal-title":"The Lancet"},{"key":"10692_CR153","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4367","author":"S Shimose","year":"2021","unstructured":"Shimose S, Hiraoka A, Nakano M, et al. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: a multicenter retrospective study. Cancer Med. 2021. https:\/\/doi.org\/10.1002\/cam4.4367","journal-title":"Cancer Med"},{"key":"10692_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96089-x","author":"A Hiraoka","year":"2021","unstructured":"Hiraoka A, Kumada T, Tada T, et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/s41598-021-96089-x","journal-title":"Sci Rep"},{"key":"10692_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.11.020","author":"AG Singal","year":"2023","unstructured":"Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib in hepatocellular carcinoma patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10692_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9","journal-title":"The Lancet"},{"key":"10692_CR157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.4019","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.4019","journal-title":"J Clin Oncol"},{"key":"10692_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30937-9","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019. https:\/\/doi.org\/10.1016\/S1470-2045(18)30937-9","journal-title":"Lancet Oncol"},{"key":"10692_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, et al. NASH limits anti-tumor surveillance in immunotherapy-treated HCC. Nature. 2021. https:\/\/doi.org\/10.1038\/s41586-021-03362-0","journal-title":"Nature"},{"key":"10692_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100702","author":"CAM Fulgenzi","year":"2023","unstructured":"Fulgenzi CAM, Scheiner B, Korolewicz J, et al. Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials. JHEP Reports. 2023. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100702","journal-title":"JHEP Reports."},{"issue":"6","key":"10692_CR161","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1007\/S11695-021-05237-9","volume":"31","author":"YP Mendoza","year":"2021","unstructured":"Mendoza YP, Becchetti C, Wan T, et al. Malnutrition and alcohol in patients presenting with severe complications of cirrhosis after laparoscopic bariatric surgery. Obes Surg. 2021;31(6):2817\u20132822. https:\/\/doi.org\/10.1007\/S11695-021-05237-9","journal-title":"Obes Surg"},{"issue":"5","key":"10692_CR162","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/J.JHEP.2018.12.014","volume":"70","author":"SE Baumeister","year":"2019","unstructured":"Baumeister SE, Schlesinger S, Aleksandrova K, et al. Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study. J Hepatol. 2019;70(5):885\u2013892. https:\/\/doi.org\/10.1016\/J.JHEP.2018.12.014","journal-title":"J Hepatol"},{"issue":"11","key":"10692_CR163","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/JNCI\/DJZ111","volume":"111","author":"SE Baumeister","year":"2019","unstructured":"Baumeister SE, Leitzmann MF, Linseisen J, Schlesinger S. Physical activity and the risk of liver cancer: a systematic review and meta-analysis of prospective studies and a bias analysis. JNCI J Nat Cancer Inst. 2019;111(11):1142. https:\/\/doi.org\/10.1093\/JNCI\/DJZ111","journal-title":"JNCI J Nat Cancer Inst"},{"issue":"2","key":"10692_CR164","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/J.CGH.2021.12.043","volume":"21","author":"HS Chun","year":"2023","unstructured":"Chun HS, Lee M, Lee HA, et al. Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(2):358-369.e12. https:\/\/doi.org\/10.1016\/J.CGH.2021.12.043","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10692_CR165","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/APT.17371","volume":"57","author":"RW Zeng","year":"2023","unstructured":"Zeng RW, Yong JN, Tan DJH, et al. Meta-analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment Pharmacol Ther. 2023;57(6):600\u2013609. https:\/\/doi.org\/10.1111\/APT.17371","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10692_CR166","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/CEJ.0000000000000663","volume":"31","author":"Y Liu","year":"2022","unstructured":"Liu Y, Ren T, Xu X, Jin J. Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies. Eur J Cancer Prev. 2022;31(1):35\u201343. https:\/\/doi.org\/10.1097\/CEJ.0000000000000663","journal-title":"Eur J Cancer Prev"},{"issue":"4","key":"10692_CR167","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/S00228-021-03247-1","volume":"78","author":"M Yi","year":"2022","unstructured":"Yi M, Feng X, Peng W, Teng F, Tang Y, Chen Z. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease. Eur J Clin Pharmacol. 2022;78(4):647\u2013656. https:\/\/doi.org\/10.1007\/S00228-021-03247-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10692_CR168","doi-asserted-by":"publisher","first-page":"E293","DOI":"10.1097\/MCG.0000000000001693","volume":"56","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang M, Liu C, Wang W, Shi J, Dang S. Aspirin use and the risk of hepatocellular carcinoma: a meta-analysis. J Clin Gastroenterol. 2022;56(7):E293\u2013E302. https:\/\/doi.org\/10.1097\/MCG.0000000000001693","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10692_CR169","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/APT.16515","volume":"54","author":"RZH Tan","year":"2021","unstructured":"Tan RZH, Lockart I, Abdel Shaheed C, Danta M. Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021;54(4):356\u2013367. https:\/\/doi.org\/10.1111\/APT.16515","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10692_CR170","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/HEP4.1640","volume":"5","author":"ZN Memel","year":"2020","unstructured":"Memel ZN, Arvind A, Moninuola O, et al. Aspirin use is associated with a reduced incidence of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Commun. 2020;5(1):133\u2013143. https:\/\/doi.org\/10.1002\/HEP4.1640","journal-title":"Hepatol Commun"},{"key":"10692_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2019.104585","author":"S Wang","year":"2020","unstructured":"Wang S, Yu Y, Ryan PM, et al. Association of aspirin therapy with risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants. Pharmacol Res. 2020. https:\/\/doi.org\/10.1016\/J.PHRS.2019.104585","journal-title":"Pharmacol Res"},{"key":"10692_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLINRE.2021.101781","author":"Q Li","year":"2022","unstructured":"Li Q, Xu H, Sui C, Zhang H. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. Clin Res Hepatol Gastroenterol. 2022. https:\/\/doi.org\/10.1016\/J.CLINRE.2021.101781","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10692_CR173","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006888","author":"S Ma","year":"2017","unstructured":"Ma S, Zheng Y, Xiao Y, Zhou P, Tan H. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine. 2017. https:\/\/doi.org\/10.1097\/MD.0000000000006888","journal-title":"Medicine"},{"key":"10692_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/SREP33743","author":"YY Zhou","year":"2016","unstructured":"Zhou YY, Zhu GQ, Liu T, et al. Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/SREP33743","journal-title":"Sci Rep"},{"issue":"1","key":"10692_CR175","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3109\/00365521.2012.719926","volume":"48","author":"H Zhang","year":"2013","unstructured":"Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol. 2013;48(1):78\u201387. https:\/\/doi.org\/10.3109\/00365521.2012.719926","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10692_CR176","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/AJG.2013.5","volume":"108","author":"S Singh","year":"2013","unstructured":"Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108(6):881\u2013891. https:\/\/doi.org\/10.1038\/AJG.2013.5","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10692_CR177","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/MEG.0000000000002040","volume":"33","author":"J Wang","year":"2021","unstructured":"Wang J, Li X. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(12):1603\u20131609. https:\/\/doi.org\/10.1097\/MEG.0000000000002040","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10692_CR178","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/MCG.0000000000001478","volume":"55","author":"YJ Wong","year":"2021","unstructured":"Wong YJ, Qiu TY, Ng GK, Zheng Q, Teo EK. Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients: a systematic review and meta-analysis. J Clin Gastroenterol. 2021;55(7):615\u2013623. https:\/\/doi.org\/10.1097\/MCG.0000000000001478","journal-title":"J Clin Gastroenterol"},{"key":"10692_CR179","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820934881","author":"Y Chang","year":"2020","unstructured":"Chang Y, Liu Q, Zhou Z, et al. Can statin treatment reduce the risk of hepatocellular carcinoma? a systematic review and meta-analysis. Technol Cancer Res Treat. 2020. https:\/\/doi.org\/10.1177\/1533033820934881","journal-title":"Technol Cancer Res Treat"},{"key":"10692_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS12040874","author":"A Facciorusso","year":"2020","unstructured":"Facciorusso A, El Aziz MAA, Singh S, et al. Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/CANCERS12040874","journal-title":"Cancers (Basel)"},{"key":"10692_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/S12876-019-1147-1","author":"Y Gu","year":"2019","unstructured":"Gu Y, Yang X, Liang H, Li D. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019. https:\/\/doi.org\/10.1186\/S12876-019-1147-1","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10692_CR182","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/J.GASTRO.2012.10.005","volume":"144","author":"S Singh","year":"2013","unstructured":"Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323\u2013332. https:\/\/doi.org\/10.1053\/J.GASTRO.2012.10.005","journal-title":"Gastroenterology"},{"issue":"3","key":"10692_CR183","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/CEJ.0B013E328358761A","volume":"22","author":"D Pradelli","year":"2013","unstructured":"Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev. 2013;22(3):229\u2013234. https:\/\/doi.org\/10.1097\/CEJ.0B013E328358761A","journal-title":"Eur J Cancer Prev"},{"issue":"12","key":"10692_CR184","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/JAMAONCOL.2018.4154","volume":"4","author":"TG Simon","year":"2018","unstructured":"Simon TG, Ma Y, Ludvigsson JF, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 2018;4(12):1683\u20131690. https:\/\/doi.org\/10.1001\/JAMAONCOL.2018.4154","journal-title":"JAMA Oncol"},{"issue":"4","key":"10692_CR185","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/J.CLD.2020.06.002","volume":"24","author":"TG Simon","year":"2020","unstructured":"Simon TG, Chan AT. Lifestyle and environmental approaches for the primary prevention of hepatocellular carcinoma. Clin Liver Dis. 2020;24(4):549. https:\/\/doi.org\/10.1016\/J.CLD.2020.06.002","journal-title":"Clin Liver Dis"},{"issue":"5","key":"10692_CR186","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/J.JHEP.2021.07.025","volume":"75","author":"NF Lange","year":"2021","unstructured":"Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention. J Hepatol. 2021;75(5):1217\u20131227. https:\/\/doi.org\/10.1016\/J.JHEP.2021.07.025","journal-title":"J Hepatol"},{"issue":"22","key":"10692_CR187","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMRA052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garc\u00eda Rodr\u00edguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373\u20132383. https:\/\/doi.org\/10.1056\/NEJMRA052717","journal-title":"N Engl J Med"},{"issue":"6","key":"10692_CR188","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1053\/J.GASTRO.2014.08.038","volume":"147","author":"S Yoshida","year":"2014","unstructured":"Yoshida S, Ikenaga N, Liu SB, et al. Extrahepatic platelet-derived growth factor-\u03b2, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014;147(6):1378\u20131392. https:\/\/doi.org\/10.1053\/J.GASTRO.2014.08.038","journal-title":"Gastroenterology"},{"issue":"4","key":"10692_CR189","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/S41591-019-0379-5","volume":"25","author":"M Malehmir","year":"2019","unstructured":"Malehmir M, Pfister D, Gallage S, et al. Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med. 2019;25(4):641\u2013655. https:\/\/doi.org\/10.1038\/S41591-019-0379-5","journal-title":"Nat Med"},{"issue":"19","key":"10692_CR190","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1158\/1078-0432.CCR-13-0203","volume":"19","author":"L Zheng","year":"2013","unstructured":"Zheng L, Yang W, Wu F, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 2013;19(19):5372\u20135380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0203","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10692_CR191","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/CNCR.29912","volume":"122","author":"DK Deperalta","year":"2016","unstructured":"Deperalta DK, Wei L, Ghoshal S, et al. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer. 2016;122(8):1216\u20131227. https:\/\/doi.org\/10.1002\/CNCR.29912","journal-title":"Cancer"},{"issue":"4","key":"10692_CR192","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/J.JHEP.2018.11.034","volume":"70","author":"S de Oliveira","year":"2019","unstructured":"de Oliveira S, Houseright RA, Graves AL, et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol. 2019;70(4):710\u2013721. https:\/\/doi.org\/10.1016\/J.JHEP.2018.11.034","journal-title":"J Hepatol"},{"issue":"37","key":"10692_CR193","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1021\/ACS.BIOCHEM.0C00476","volume":"59","author":"G Alipour Talesh","year":"2020","unstructured":"Alipour Talesh G, Trezeguet V, Merched A. Hepatocellular carcinoma and statins. Biochemistry. 2020;59(37):3393\u20133400. https:\/\/doi.org\/10.1021\/ACS.BIOCHEM.0C00476","journal-title":"Biochemistry"},{"key":"10692_CR194","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5389044","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang W, Wang M, Shi J, Jia X, Dang S. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2022. https:\/\/doi.org\/10.1155\/2022\/5389044","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10692_CR195","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20200232","author":"X Li","year":"2020","unstructured":"Li X, Liu L, Hu Y. Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis. 2020. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20200232"},{"issue":"2","key":"10692_CR196","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/CLD.568","volume":"8","author":"J Choi","year":"2016","unstructured":"Choi J, Roberts LR. Statins and metformin for chemoprevention of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2016;8(2):48\u201352. https:\/\/doi.org\/10.1002\/CLD.568","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10692_CR197","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25536","author":"SK Reddy","year":"2012","unstructured":"Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012. https:\/\/doi.org\/10.1002\/hep.25536","journal-title":"Hepatology"},{"key":"10692_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.07.015","author":"S Conci","year":"2022","unstructured":"Conci S, Cipriani F, Donadon M, et al. Hepatectomy for metabolic associated fatty liver disease (MAFLD) related HCC: propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol. 2022. https:\/\/doi.org\/10.1016\/j.ejso.2021.07.015","journal-title":"Eur J Surg Oncol"},{"key":"10692_CR199","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1197-x","author":"A Weinmann","year":"2015","unstructured":"Weinmann A, Alt Y, Koch S, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015. https:\/\/doi.org\/10.1186\/s12885-015-1197-x","journal-title":"BMC Cancer"},{"key":"10692_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.11.012","author":"J Best","year":"2020","unstructured":"Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020. https:\/\/doi.org\/10.1016\/j.cgh.2019.11.012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10692_CR201","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005642","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Li T, Qiu Y, et al. Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. Medicine (United States). 2017. https:\/\/doi.org\/10.1097\/MD.0000000000005642","journal-title":"Medicine (United States)"},{"key":"10692_CR202","doi-asserted-by":"publisher","DOI":"10.1159\/000492254","author":"Y Mei","year":"2018","unstructured":"Mei Y, You Y, Xia J, Gong JP, Wang YB. Identifying differentially expressed micrornas between cirrhotic and non-cirrhotic hepatocellular carcinoma and exploring their functions using bioinformatic analysis. Cell Physiol Biochem. 2018. https:\/\/doi.org\/10.1159\/000492254","journal-title":"Cell Physiol Biochem"},{"key":"10692_CR203","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15763","author":"M Sato","year":"2022","unstructured":"Sato M, Kobayashi T, Soroida Y, et al. Development of novel deep multimodal representation learning-based model for the differentiation of liver tumors on B-mode ultrasound images. J Gastroenter Hepat (Australia). 2022. https:\/\/doi.org\/10.1111\/jgh.15763","journal-title":"J Gastroenter Hepat (Australia)."},{"key":"10692_CR204","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-02021-7","author":"H Crane","year":"2023","unstructured":"Crane H, Gofton C, Sharma A, George J. MAFLD: an optimal framework for understanding liver cancer phenotypes. J Gastroenterol. 2023. https:\/\/doi.org\/10.1007\/s00535-023-02021-7","journal-title":"J Gastroenterol"},{"key":"10692_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/nature14851","author":"JS Bajaj","year":"2015","unstructured":"Bajaj JS, Betrapally NS, Gillevet PM. Decompensated cirrhosis and microbiome interpretation. Nature. 2015. https:\/\/doi.org\/10.1038\/nature14851","journal-title":"Nature"},{"key":"10692_CR206","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0074","author":"MR de Galarreta","year":"2019","unstructured":"de Galarreta MR, Bresnahan E, Molina-S\u00e1nchez P, et al. \u03b2-catenin activation promotes immune escape and resistance to anti\u2013PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0074","journal-title":"Cancer Discov"},{"key":"10692_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194631","author":"M Pallozzi","year":"2022","unstructured":"Pallozzi M, Di Tommaso N, Maccauro V, et al. Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14194631","journal-title":"Cancers (Basel)."}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10692-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10692-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10692-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T14:06:47Z","timestamp":1727964407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10692-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":207,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10692"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10692-4","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"3 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Argenziano Maria Eva declares that he has no conflict of interest.Kim Mi Na declares that he has no conflict of interest. Montori Michele declares that he has no conflict of interest. Di Bucchianico Alessandro declares that he has no conflict of interest. Balducci Daniele declares that he has no conflict of interest. Sang Hoon Ahn declares that he has no conflict of interest. Svegliati Baroni Gianluca declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}